AutoICD API

94077-5

Laboratory

Tumor mutation burden [Interpretation]

Definition

Tumor mutational burden (TMB), also known as mutation load, is a biomarker for various cancer types to identify patients who will benefit from immunotherapy, such as immune checkpoint blockade (ICB) therapy. Testing can be performed by whole exome sequencing (WES) or next-generation sequencing (NGS). Various quantitative and ordinal results may be reported, so it is important to distinguish the type of results when mapping to LOINC. Quantitative results typically include the number of mutations detected per megabase (mut/Mb), often by NGS, in a tumor specimen [LOINC: 94076-7]. The mutations targeted may include non-synonymous or both synonymous and non-synonymous mutations. Quantitative TMB results have also been reported as the total number of mutations detected by whole exome sequencing (WES). We encourage labs to report how results are determined or calculated in either the structured message format or using another LOINC. An ordinal TMB result (this term) of high, low, etc., may also be reported to provide an overall interpretation for the quantitative value (muts/Mb). Cut-offs vary across assays and for each tumor type, so it is important to know which assay was used to determine the overall ordinal TMB result.

LOINC 6-Axis Classification

Component

Tumor mutation burden

Property

Imp

Time Aspect

Pt

System

Tumor

Scale Type

Ord

Method Type

N/A

Details

Class

MOLPATH.MUT

Order/Observation

Both

Short Name

TMB Tumor-Imp

Display Name

Tumor mutation burden Ql (Tumor) [Interp]

Related Names

CancerImpressionImpression/interpretation of studyImpressionsInterpInterpretationMolecular pathologyMOLPATHMOLPATH.MUTATIONSMutMutationsOrdinalPoint in timeQLQualQualitativeRandomScreenTMBTumor mutational loadtumorstumourtumours

Frequently Asked Questions

What is LOINC code 94077-5?

LOINC code 94077-5 identifies "Tumor mutation burden [Interpretation]". Tumor mutational burden (TMB), also known as mutation load, is a biomarker for various cancer types to identify patients who will benefit from immunotherapy, such as immune checkpoint blockade (ICB) therapy. Testing can be performed by whole exome sequencing (WES) or next-generation sequencing (NGS). Various quantitative and ordinal results may be reported, so it is important to distinguish the type of results when mapping to LOINC. Quantitative results typically include the number of mutations detected per megabase (mut/Mb), often by NGS, in a tumor specimen [LOINC: 94076-7]. The mutations targeted may include non-synonymous or both synonymous and non-synonymous mutations. Quantitative TMB results have also been reported as the total number of mutations detected by whole exome sequencing (WES). We encourage labs to report how results are determined or calculated in either the structured message format or using another LOINC. An ordinal TMB result (this term) of high, low, etc., may also be reported to provide an overall interpretation for the quantitative value (muts/Mb). Cut-offs vary across assays and for each tumor type, so it is important to know which assay was used to determine the overall ordinal TMB result.

What does 94077-5 measure?

This code measures Tumor mutation burden in Tumor. It belongs to the MOLPATH.MUT class in the LOINC classification.

What is LOINC?

LOINC (Logical Observation Identifiers Names and Codes) is a universal standard for identifying laboratory and clinical observations. It is maintained by the Regenstrief Institute and used worldwide for health data exchange.